1. Stem Cell Therapy

Category Archives: Stem Cell Therapy

Treatment for Degenerative, Bulging and Herniated Discs Minimally Invasive Stem Cell Therapy – Video

Posted on by


Treatment for Degenerative, Bulging and Herniated Discs Minimally Invasive Stem Cell Therapy
Treatment for Bulging and Herniated Discs in Thailand http://stemcellthailand.org/services-list/stem-cell-treatment-degenerative-disc-disease-back-surgery-al...

By: Regeneration Center of Thailand

See the rest here:

Treatment for Degenerative, Bulging and Herniated Discs Minimally Invasive Stem Cell Therapy - Video

Stem Cell Therapy | bone marrow concentrate for osteoarthritis – Video

Posted on by


Stem Cell Therapy | bone marrow concentrate for osteoarthritis
http://www.arthritistreatmentcenter.com In the next video I #39;ll report on another study showing the effectiveness of stem cells in the treatment of osteoarthritis... New Study Shows Positive...

By: Nathan Wei

Read this article:

Stem Cell Therapy | bone marrow concentrate for osteoarthritis - Video

Stemcell therapy 'adversely effected' 2025% of patients

Posted on by

Stamina risks range from nausea to cancer, prosecutors say

(ANSA) - Turin, April 24 - Between 20% and 25% of Italian patients treated with a recently discredited stem-cell therapy called Stamina experienced "adverse effects", medical consultants said in a report submitted to prosecutors in Turin on Thursday. Such effects, said the report, had not been reported to health officials. Earlier Thursday, Turin investigators submitted a report that said risks of the treatment range from nausea to cancer. Prosecutors concluded a probe Wednesday of 20 suspects involved in the Stamina treatment, including Davide Vannoni, founder of the Stamina Foundation, who may face indictment. Charges could include criminal association to commit aggravated fraud and administration of dangerous drugs, according to prosecutors whose probe examined the treatment of slightly more than 100 patients. Another 37 donors of stem cells used in the controversial treatment, rejected by the health ministry, were examined during the investigation. According to prosecutors, Vannoni and other suspects "pretended" that there was a "high chance" of recovery from serious illness if patients agreed to the Stamina treatment. Earlier this month, hospitals in Italy that used the discredited stem-cell treatment announced they had suspended the program. That followed announcements last fall by Italy's health ministry that the Stamina Foundation - the nonprofit foundation that developed the treatment - would not be allowed to test it on humans. The foundation was also stripped of its non-profit status after a study found its treatment was "ignorant of stem-cell biology".

View post:

Stemcell therapy 'adversely effected' 2025% of patients

More Media Coverage for MediVet Stem Cell Therapy at Newman Veterinary Centers – Central Florida – Video

Posted on by


More Media Coverage for MediVet Stem Cell Therapy at Newman Veterinary Centers - Central Florida
We are proud to offer this amazing procedure at Newman Veterinary Centers. Stem cell therapy can help pets with arthritis, hip dysplasia and many other degen...

By: Newman Veterinary Centers

See more here:
More Media Coverage for MediVet Stem Cell Therapy at Newman Veterinary Centers - Central Florida - Video

Autologous stem cell therapy improves motor function in chronic stroke victims

Posted on by

PUBLIC RELEASE DATE:

23-Apr-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Apr. 23, 2014) People who have had a stroke, often suffer motor deficits with little potential to restore neurological function. However, a study conducted in Taiwan, that will be published in a future issue of Cell Transplantation, but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen, has found that when one group of stroke victims had their own peripheral blood stem cells (PBSCs) injected directly into the brain and a similar group did not, those who received the PBSCs experienced some "improvement in stroke scales and functional outcome." Those in the PBSC-injected group also received injections of the growth factor granulocyte-colony stimulating factor (G-CSF), known to be potentially neuroprotective.

"In this phase 2 study, we provide the first evidence that intracerebral injection of autologous (self-donated) PBSCs can improve motor function in those who have suffered a stroke and have motor deficits as a result," said study corresponding Dr. Woei-Cheng Shyu of the Center for Neuropsychiatry, Graduate Institute of Immunology and Translational Medicine Research Center, China Medical University in Taiwan. "Our study demonstrated that this therapeutic strategy was feasible and safe in stroke patients who suffered a prior stroke, but within five years from the onset of symptoms."

According to the authors, there has been little advance made in restoring neurological function following ischemic stroke. However, since neuronal death is the primary mechanism that limits functional recovery, stem cell therapy is emerging as a potentially effective regenerative approach. Once more PBSCs are being increasingly used as a self-donated source for cell therapies for regenerating skeletal muscle, heart and neurons. The PBSCs may need to be "amplified" with G-CSF, speculated the researchers.

All of the patients in the trial had suffered a stroke in the past, as long as five years prior to this study. At the end of a 12 month follow-up, the group of 15 patients with neurological deficits who received injections of PBSCs experienced neurological and functional improvement based on a number of clinical outcomes measures. The control group of 15 patients with neurological deficits that did not receive the PBSC injections did not experience the same beneficial outcomes.

The researchers reported that nine of the 15 patients undergoing PBSC transplantation experienced "positive motor evoked potentials" (MEPs) after transcranial magnetic stimulation, but why MEPs appeared in some of the transplanted group, but not all, was unclear.

"Despite this success, it should be noted that this was a preliminary study and, due to the small number of patients, are tentative," concluded the researchers. "In the future we plan to conduct a multi-center, large-scale, double blind, placebo-controlled randomized studies to better evaluate the effect of PBSC implantation in patients suffering from the effects of past stroke."

"This phase II study offers pilot clinical evidence supporting the use of autologous stem cell-based treatment for stroke" said Dr. Cesar V. Borlongan, Prof. of Neurosurgery and Director of the Center of Excellence for Aging & Brain Repair at the University of South Florida. "Clarification of the impact of G-CSF on the cells and whether other factors are necessary to maximize the benefit of cell transplantation, as well as further studies with a larger number of patients are necessary to determine equivocal safety and efficacy of this treatment".

Follow this link:
Autologous stem cell therapy improves motor function in chronic stroke victims

Study finds long-term survival of human neural stem cells transplanted into primate brain

Posted on by

PUBLIC RELEASE DATE:

23-Apr-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Apr. 23 2014) A team of researchers in Korea who transplanted human neural stem cells (hNSCs) into the brains of nonhuman primates and assessed cell survival and differentiation after 22 and 24 months found that the hNSCs had differentiated into neurons at 24 months and did not cause tumors.

The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1117Antonucci2.

The hNSCs were labeled with magnetic nanoparticles to enable them to be followed by magnetic resonance imaging (MRI). They did not use immunosuppressants. According to the researchers, their study is the first to evaluate and show the long-term survival and differentiation of hNSCs without the need for immunosuppression.

The researchers concluded that hNSCs could be of "great value" as a source for cell replacement and gene transfer for the treatment of Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal cord injury and stroke.

"Stroke is the fourth major cause of death in the US behind heart failure, cancer, and lower respiratory disease," said study co-author Dr. Seung U. Kim of University of British Columbia Hospital's department of neurology in Canada. "While tissue plasminogen activator (tPA) treatment within three hours after a stroke has shown good outcomes, stem cell therapy has the potential to address the treatment needs of those stroke patients for whom tPA treatment was unavailable or did not help."

Dr. Kim and colleagues in Korea grafted magnetic particle-labeled hNSCs into the brains of laboratory primates and evaluated their performance to assess their survival and differentiation over 24 months. Of particular interest was determining their ability to differentiate into neurons and to determine whether the cells caused tumorogenesis.

"We injected hNSCs into the frontal lobe and the putamen of the monkey brain because they are included in the middle cerebral artery (MCA) territory, which is the main target in the development of the ischemic lesion in animal stroke models," commented Dr. Kim. "Thus, research on survival and differentiation of hNSCs in the MCA territory should provide more meaningful information to cell transplantation in the MCA occlusion stroke model."

See the article here:
Study finds long-term survival of human neural stem cells transplanted into primate brain

Scientists identify cancer specific cell for potential treatment of gastric cancer

Posted on by

PUBLIC RELEASE DATE:

23-Apr-2014

Contact: Kimberley Wang kimberley.wang@nus.edu.sg National University of Singapore

A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.

The research group, led by Dr Chan Shing Leng, Research Assistant Professor at CSI Singapore, demonstrated for the first time that a cancer-specific variant of a cell surface protein, CD44v8-10, marks gastric cancer stem cells but not normal cells. Conceptualised by Dr Chan and Associate Professor Jimmy So, a Senior Consultant from the Department of Surgery at the National University Hospital Singapore, the study is also the first to be conducted with human gastric tissue specimens and took five years to complete. This novel study will be published in the research journal Cancer Research, the official journal of American Association of Cancer Research, in May 2014.

Gastric cancer is a major cause of cancer-related deaths worldwide, with low survival and high recurrence rates for patients with advanced disease. New therapies for the treatment of gastric cancer are urgently needed.

How CD44v8-10 serves as a biomarker

Many cancer cell types express high levels of a cell surface protein known as CD44. This protein marks cancer stem cells that are thought to be responsible for resistance to current cancer therapy and tumour relapse. There are many forms of CD44 and the standard form of CD44, CD44s, is found in high abundance on normal blood cells. It was previously not known which form of CD44 is found on cancer stem cells. This is critical as an ideal cancer target should mark only cancer cells but not normal cells.

Research by the team and other scientists in the field has led to the hypothesis that the growth of gastric cancer may be driven by cancer stem cells. In this study, the researchers analysed 53 patient tissue samples in conjunction with patient-derived xenograft models which are derived from intestinal type gastric cancer. The team is one of the few groups in the world to have a relatively large collection of patient-derived xenograft models for gastric cancer and the first to use these models for identification of gastric cancer stem cells. A total of eight cancer cell lines were used in this study, including six new cell lines which were established by the researchers.

The scientists discovered a cancer-specific CD44 variant, CD44v8-10 marks gastric cancer stem cells but not normal cells. CD44v8-10 promotes cancer cell growth and it is significantly more abundant in gastric tumour sites compared to normal gastric tissue, which makes it easily detectable. The findings results suggest that CD44v8-10 is an ideal target for developing clinical therapeutics against gastric cancer stem cells. As CD44v8-10 is cancer specific, it may also be used as a biomarker for screening and diagnosis of gastric cancer. This is significant as biomarkers for early detection of gastric cancer are currently not available and doctors rely on endoscopy for the screening and diagnosis of this disease.

The rest is here:
Scientists identify cancer specific cell for potential treatment of gastric cancer

Scientists Identify Cancer Specific Cell for Potential Targeted Treatment of Gastric Cancer

Posted on by

Contact Information

Available for logged-in reporters only

Newswise A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.

The research group, led by Dr Chan Shing Leng, Research Assistant Professor at CSI Singapore, demonstrated for the first time that a cancer-specific variant of a cell surface protein, CD44v8-10, marks gastric cancer stem cells but not normal cells. Conceptualised by Dr Chan and Associate Professor Jimmy So, a Senior Consultant from the Department of Surgery at the National University Hospital Singapore, the study is also the first to be conducted with human gastric tissue specimens and took five years to complete. This novel study will be published in the research journal Cancer Research, the official journal of American Association of Cancer Research, in May 2014.

Gastric cancer is a major cause of cancer-related deaths worldwide, with low survival and high recurrence rates for patients with advanced disease. New therapies for the treatment of gastric cancer are urgently needed.

How CD44v8-10 serves as a biomarker

Many cancer cell types express high levels of a cell surface protein known as CD44. This protein marks cancer stem cells that are thought to be responsible for resistance to current cancer therapy and tumour relapse. There are many forms of CD44 and the standard form of CD44, CD44s, is found in high abundance on normal blood cells. It was previously not known which form of CD44 is found on cancer stem cells. This is critical as an ideal cancer target should mark only cancer cells but not normal cells.

Research by the team and other scientists in the field has led to the hypothesis that the growth of gastric cancer may be driven by cancer stem cells. In this study, the researchers analysed 53 patient tissue samples in conjunction with patient-derived xenograft models which are derived from intestinal type gastric cancer. The team is one of the few groups in the world to have a relatively large collection of patient-derived xenograft models for gastric cancer and the first to use these models for identification of gastric cancer stem cells. A total of eight cancer cell lines were used in this study, including six new cell lines which were established by the researchers.

The scientists discovered a cancer-specific CD44 variant, CD44v8-10 marks gastric cancer stem cells but not normal cells. CD44v8-10 promotes cancer cell growth and it is significantly more abundant in gastric tumour sites compared to normal gastric tissue, which makes it easily detectable. The findings results suggest that CD44v8-10 is an ideal target for developing clinical therapeutics against gastric cancer stem cells. As CD44v8-10 is cancer specific, it may also be used as a biomarker for screening and diagnosis of gastric cancer. This is significant as biomarkers for early detection of gastric cancer are currently not available and doctors rely on endoscopy for the screening and diagnosis of this disease.

Said Dr Chan, With our findings, we can now work on developing drugs that would recognise and attack the cancer stem cells only, reducing the side effects on normal cells. With additional funding, we aim to have a drug that can show efficacy in our models within three years.

Original post:

Scientists Identify Cancer Specific Cell for Potential Targeted Treatment of Gastric Cancer

Irish cell therapy firm in E6m research

Posted on by

Tuesday, April 22 11:57:06

Orbsen Therapeutics, a spin-out from NUI Galway's Regenerative Medicine Institute (REMEDI), is to partner with the University of Birmingham in a E6 million EU FP7 funded MERLIN project to fight liver disease.

The EU FP7-funded project known by the acronym "MERLIN" (MEsynchymal stem cells to Reduce Liver INflammation) is led by Professor Phil Newsome, Clinical Director of the Birmingham University Stem Cell Centre. MERLIN will advance Orbsen's proprietary cell therapy to a Phase 2a clinical trial in patients with inflammatory liver disease. This MERLIN project will evaluate the Orbsen cell therapy in 4 different research laboratories across Europe and the project will culminate in a Phase 2a clinical trial of the therapy in the crippling inflammatory liver disease, Primary Sclerosing Cholangitis.

This is Orbsen's fourth success in attracting FP7 funding (the EU's Seventh Framework Programme for Research), making them one of Ireland's most successful private companies in this funding programme and now connects Orbsen to 23 global collaborators. Other successful cell therapy projects for Orbsen include PURSTEM (completed), REDDSTAR (ongoing) and DeCIDE (ongoing).

Orbsen Therapeutics Ltd. is a privately-held company founded in 2006 as a spin-out from Ireland's Regenerative Medicine Institute (REMEDI) in NUI Galway. As part of the PurStem EU FP7 program, Orbsen developed proprietary technologies that enable the prospective purification of highly defined and therapeutic (stromal) cells from several human tissues, including bone marrow, adipose tissue and umbilical cord.

Orbsen's CEO Brian Molloy said, "Orbsen has secured substantial amounts of research funding in the last 18 months which will further validate our product and bring us through to a "first in man" clinical trial in 2015/16. Our model has always focused on putting the 'science first' and we have successfully used that approach to develop a technology that could potentially position us and indeed Ireland at the leading edge of European Cell Therapy development."

Mr Molloy continued, "As a spin-out from the NUI Galway based REMEDI Institute we have focused the majority of our collaborations with an Irish research team. Our success in the MERLIN project now demonstrates that we are capable of playing a key role in collaborations led by researchers across Europe."

The total research budget for the MERLIN project is close to E6 Million of which E1 Million will go directly to Orbsen Therapeutics over the 4-year period of the project.

Excerpt from:
Irish cell therapy firm in E6m research

stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation – Video

Posted on by


stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation
improvement seen in just 3 months after stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation by dr alok sharma, mumbai, ...

By: Neurogen Brain and Spine Institute

Here is the original post:
stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation - Video

stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok – Video

Posted on by


stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok
improvement seen in just 3 months after stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok sharma, mumbai, ind...

By: Neurogen Brain and Spine Institute

Read the original here:
stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok - Video

Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic …

Posted on by

Phoenix, Arizona (PRWEB) April 21, 2014

The top foot and ankle specialists in Arizona at Valley Foot Surgeons are now offering stem cell treatments for diabetic wounds. The treatments may propel these difficult wounds to heal in a much shorter time frame than they would without regenerative medicine therapy. The stem cell doctor is a four-time Phoenix Magazine Top Doc Winner; call (480) 994-5977 for more information and scheduling.

With up to a third of individuals suffering from diabetes (or pre-diabetes), wounds and ulcers are becoming more common all the time in the foot and ankle area. Due to the immunocompromised state of diabetics, it can be extremely difficult for the human body to naturally heal these wounds. Sometimes, they persist for years, become infected, and may lead to an eventual need for an amputation.

At Valley Foot Surgeons, Phoenix Top Doc Richard Jacoby is now offering stem cell treatments for diabetic wounds. These treatments are performed as an outpatient and involve subcutaneous injections of amniotic derived stem cell material around the wound.

The procedure offers several benefits in addition to a hefty concentration of stem cells. The material is immunologically privileged and does not cause a rejection reaction. It is processed from an FDA regulated lab.

The amniotic derived stem cells assists with the creation of new blood vessels to help heal the wounds and also contains a significant amount of growth factors. The stem cell material also has antimicrobial properties, helping avoid infection.

Along with the stem cell procedures, Valley Foot Surgeons offers laser treatment simultaneously which further helps with the healing process. With approximately 100 stem cell procedures performed so far for diabetic wounds, the outcomes have been nothing short of incredible.

Wounds have been healing, and much faster than with conventional methods. For more information and treatment with the top foot and ankle stem cell doctor in Phoenix and Scottsdale, call (480) 420-3499.

Read the original:
Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic ...


  1. Stem Cell Therapy